Comparing resource utilization and gastrointestinal outcomes in patients treated with either standard-dose or high-dose proton pump inhibitors: A matched cohort study

Digestive Diseases and Sciences

Volumn 53, Issue 6, 2008, Pages 1519-1526

  Targownik, Laura E ^a,b,c   Metge, Colleen ^a,c,d   Leung, Stella ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Gastroesophageal reflux disease; Pharmacoepidemiology; Proton pump inhibitors; Resource utilization

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG MEGADOSE; DRUG USE; DRUG UTILIZATION; DUODENUM ULCER; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HIATUS HERNIA; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; STANDARD; STOMACH ULCER; THORAX PAIN; TREATMENT DURATION;

CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DELIVERY OF HEALTH CARE; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MANITOBA; PROTON PUMP INHIBITORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 43049116884     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0031-y     Document Type: Article

References (45)

1. Talley NJ (2004) What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 20 [Suppl 2]:23-30
2. Source: IMS Health, IMS National Sales Perspectives™, 2/2005. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_69890098,00. html Accessed 31 March 2006
3. Hungin AP, Rubin GP, O'Flanagan H (1999) Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 49(443):451-453
4. DeVault KR, Castell DO, American College of Gastroenterology (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190-200
5. Dean BB, Gano AD Jr, Knight K et al (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2(8):656-664
6. Talley NJ, Vakil N (2005) Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 100(10):2324-2327
7. Peura DA (2004) Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 117 [Suppl 5A]:63S-71S
8. Hunt RH (1999) Importance of pH control in the management of GERD. Arch Intern Med 159(7):649-657
9. Howden CW, Burget DW, Hunt RH (1994) Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 201:79-82
10. Cremonini F, Wise J, Moayyedi P, Talley NJ (2005) Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta analysis. Am J Gastroenterol 100(6):1226-1232
11. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB (2000) The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 14(4):389-396
12. Talley NJ, Moore MG, Sprogis A, Katelaris P (2002) Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 177(8):423-427
13. Fass R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22(2):79-94
14. Ofman JJ, Dorn GH, Fennerty MB, Fass R (2002) The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16(2):261-273
15. Roos NP, Shapiro E (1999) Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37:JS10-JS14
16. Roos NP (1999) Establishing a population data-based policy unit. Med Care 37:JS15-JS26
17. Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32(11):1152-1157
18. Robinson JR, Young TK, Roos LL, Gelsky DE (1997) Estimating the burden of disease: comparing administrative data and self-reports. Med Care 35(9):932-947
19. Huzel L, Roos LL, Anthonisen NR, Manfreda J (2003) Diagnosing asthma: the fit between survey and administrative database. Can Respir J 9(6):407-412
20. Metge CJ, Black C, Peterson S, Kozyrskyj AL (1999) The population's use of pharmaceuticals. Med Care 37 [6Suppl]:JS42-JS59
21. Metge CJ, Blanchard JF, Peterson S, Bernstein CN (2001) Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 96(12):3348-3355
22. Starfield B, Weiner J, Mumford L, Steinwachs D (1991) Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 26:53-74
23. Smith NS, Weiner JP (1994) Applying population-based case mix adjustment in managed care: the Johns Hopkins Ambulatory Care Group system. Manag Care Q 2:21-34
24. Mustard CA, Derksen S, Berthelot JM, Wolfson M (1999) Assessing ecologic proxies for household income: a comparison of household and neighbourhood-level income measures in the study of population health status. Health Place 5(2):157-171
25. Meineche-Schmidt V (2004) Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption. Am J Gastroenterol 99(6):1050-1058
26. Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA (1998) A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 93(2):238-243
27. Sontag SJ, Hirschowitz BI, Holt S et al (1992) Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 102(1):109-118
28. Bardhan KD, Hawkey CJ, Long RG et al (1995) Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 9(2):145-151
29. Van Rensburg CJ, Honiball PJ, Grundling HD et al (1996) Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 10(3):397-401
30. Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine Versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726
31. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 38(11):727-734
32. Avner DL, Dorsch ER, Jennings DE, Greski-Rose PA (1995) A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. Aliment Pharmacol Ther 9(5):521-528
33. Avner DL, Movva R, Nelson KJ, McFarland M, Berry W, Erfling W (1995) Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. Am J Gastroenterol 90(8):1289-1294
34. Muller P, Simon B, Khalil H, Luhmann R, Leucht U, Schneider A (1992) Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 30(11):771-775
35. Scheiman JM, Yeomans ND, Talley NJ et al (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101(4):701-710
36. Sharma P, McQuaid K, Dent J et al (2004) A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127(1):310-330
37. Fass R, Ofman JJ, Gralnek IM et al (1999) Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 159(18):2161-2168
38. Sharma P, Sampliner RE, Camargo E (1997) Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 92(4):582-585
39. Cooper BT, Chapman W, Neumann CS, Gearty JC (2006) Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23(6):727-733
40. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 99(10):1877-1883
41. Martin RM, Dunn NR, Freemantle S, Shakir S (2000) The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 50(4):366-372
42. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947-2953
43. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16):1955-1960
44. Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PD (1993) Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 7(5):501-507
45. Inadomi JM, McIntyre L, Bernard L, Fendrick AM (2003) Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 98(9):1940-1944